Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasireotide and Topotecan in Relapsed SCLC
NCT01417806Phase 2Unknown
- Sponsor
- South Florida Veterans Affairs Foundation for Research and Education
- Start
- Jul 2011
- Primary completion
- Jun 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pasireotide LAR in small cell lung cancer (SCLC), sponsored by South Florida Veterans Affairs Foundation for Research and Education. Primary endpoint: Progression-Free Survival at 5 years. Status: unknown.
02
Drugs
pasireotide LAR
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01417806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01417806.